Grifols (GRFS) Intangibles (2009 - 2025)
Grifols' (GRFS) quarterly Intangibles came in at $3.2 billion in Q4 2025, up 1.56% YoY from $3.1 billion in Q4 2024, and up 1.56% on a QoQ basis from $3.1 billion in Q4 2024.
Grifols (GRFS) Intangibles (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Intangibles data on file, last reported at $3.2 billion in Q4 2025.
- Quarterly Intangibles rose 1.56% year-over-year to $3.2 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.2 billion (up 1.56% YoY) and the FY2025 annual result came in at $3.2 billion, up 1.56% from the prior year.
- Intangibles advanced to $3.2 billion in Q4 2025, from $3.1 billion in the prior quarter.
- In the past five years, Intangibles ranged from a high of $3.2 billion in Q4 2025 to a low of $1.5 billion in Q4 2023.
- A 5-year average of $2.5 billion and a median of $3.0 billion in 2022 frame the typical range for Intangibles.
- Annual changes were most pronounced in 2023 — Intangibles sank 50.33% — and 2024, when it soared 109.22%.
- Tracing GRFS's Intangibles over 5 years: stood at $1.9 billion in 2021, then jumped by 60.68% to $3.0 billion in 2022, then slumped by 50.33% to $1.5 billion in 2023, then soared by 109.22% to $3.1 billion in 2024, then gained by 1.56% to $3.2 billion in 2025.
- The last three Intangibles figures came in at $3.2 billion (Q4 2025), $3.1 billion (Q4 2024), and $1.5 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 653.37 Bn | 632.61 Bn | 17.26 Bn | 48.23 Bn |
| 2 | AbbVie | 469.65 Bn | 463.08 Bn | 12.70 Bn | 49.14 Bn |
| 3 | Merck | 376.13 Bn | 368.99 Bn | 12.21 Bn | 24.98 Bn |
| 4 | Novartis Ag | 303.28 Bn | 295.59 Bn | 11.24 Bn | 42.07 Bn |
| 5 | Astrazeneca | 258.06 Bn | 253.16 Bn | 12.86 Bn | 37.72 Bn |
| 6 | Amgen | 236.35 Bn | 222.36 Bn | 7.24 Bn | 20.49 Bn |
| 7 | Gilead Sciences | 182.15 Bn | 178.97 Bn | 6.22 Bn | 14.03 Bn |
| 8 | Pfizer | 159.57 Bn | 147.87 Bn | 10.94 Bn | 47.05 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 22.54 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 3.18 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.18 Bn |
| Dec 31, 2024 | 3.13 Bn |
| Dec 31, 2023 | 1.49 Bn |
| Dec 31, 2022 | 3.01 Bn |
| Dec 31, 2021 | 1.87 Bn |
| Dec 31, 2020 | 1.86 Bn |
| Dec 31, 2019 | 1.59 Bn |
| Dec 31, 2018 | 1.58 Bn |
| Jun 30, 2018 | 1.60 Bn |
| Dec 31, 2017 | 1.49 Bn |
| Jun 30, 2017 | 1.21 Bn |
| Dec 31, 2016 | 1.29 Bn |
| Sep 30, 2016 | 1.26 Bn |
| Jun 30, 2016 | 1.29 Bn |
| Dec 31, 2015 | 1.27 Bn |
| Sep 30, 2015 | 1.27 Bn |
| Mar 31, 2015 | 1.35 Bn |
| Dec 31, 2014 | 1.34 Bn |
| Sep 30, 2014 | 1.39 Bn |
| Jun 30, 2014 | 1.35 Bn |